Five-Grass-Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial

Allergic DiseasesImmunotherapy

STRUCTURED FRESH APPLE CONSUMPTION FOR BIRCH POLLEN FOOD ALLERGY SYNDROME IN AN UNCONTROLLED PHASE II/III TRIAL

J Allergy Clin Immunol Pract

Mueller B, Reider N, Demir H, Bohle B, Marquer L, Yildirim A, Deluca J, Cova V, Ahammer L, Eidelpes R, Unterhauser J, Tollinger M, Letschka T, Eisendle K

doi: 10.1016/j.jaip.2025.06.030

Immunodeficiency

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Lancet

Orkin C, Mngqibisa R, Velez JD, Kumar P, Braun DL, Carr A, Bloch M, Walmsley S, Tebas P, Yokomaku Y, Diamond TL, Jackson B, Eves K, Grandhi A, Fuszard M, Klopfer SO, Stamm LM, Fox MC, Kim J

doi: 10.1016/S0140-6736(25)01945-2

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Immune Response

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Lancet

Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, Tredo SR, Ramanathan R, Jenkins VA, Bedell L, Ajiboye P, EBSI-CV-317-005 Study Group

doi: 10.1016/S0140-6736(25)00372-1

Psoriasis

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

J Eur Acad Dermatol Venereol

Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, Bansal A, Dahale SS, Martin R, Paguet B, Magnolo N, Kingo K

doi: 10.1111/jdv.70155

Alopecia Areata

Efficacy and safety of Cinainu in pediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase 2/3 trial

Br J Dermatol

Blume-Peytavi U, Piraccini BM, Reygagne P, Guiraud J, Mukherjee B, Guichard A, Liu J, Pralong W, Harti S

doi: 10.1093/bjd/ljaf279

Osteoarthritis

Knee arthroplasty compared with joint distraction for osteoarthritis: a phase III randomized controlled trial

Bone Jt Open

Hamilton TW, Lineham B, Stocken DD, Pandit H, KARDS Study Group, Muli A, Kelly R, Collier H, Mujica-Mota R, Metcalfe A, Simpson H, Murray DW, Sharma H, McGonagle D, Ellard DR, Croft J, Stokes J, Harwood P

doi: 10.1302/2633-1462.68.BJO-2024-0120.R2

Immunodeficiency

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

Lancet

Colson AE, Mills AM, Ramgopal MN, Bettacchi C, Osiyemi OO, Hinestrosa F, Crofoot G, Katner HP, Gatanaga H, Johnson M, Diamond TL, Barninger E, Eves K, Su FH, Xu Y, Klopfer SO, Stamm LM, Fox MC, Lahoulou R

doi: 10.1016/S0140-6736(25)01948-8

Allergic Diseases

Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial

Allergy

Holzmann C, Karg J, Reiger M, Kharbal R, Romano P, Scheiwein S, Khalfi C, Muzalyova A, Brunner JO, Hammel G, Damialis A, Traidl-Hoffmann C, Plaza MP, Gilles S

doi: 10.1111/all.16558

Related content

STRUCTURED FRESH APPLE CONSUMPTION FOR BIRCH POLLEN FOOD ALLERGY SYNDROME IN AN UNCONTROLLED PHASE II/III TRIAL

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

Efficacy and safety of Cinainu in pediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase 2/3 trial

Knee arthroplasty compared with joint distraction for osteoarthritis: a phase III randomized controlled trial

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial